EOLS Stock Analysis: Buy, Sell, or Hold?
EOLS - Evolus, Inc. Common Stock
$4.69
0.03 (0.64%)
▲
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 03, 2026
29d
Get Alerted When EOLS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: EOLS shows positive signals but monitor for confirmation. Market pricing in 23.5% growth. Moderate conviction.
💡 BUY OPPORTUNITY: EOLS shows positive signals but monitor for confirmation. Market pricing in 23.5% growth. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: EOLS is currently trading at $4.69, which is considered oversold relative to its 30-day fair value range of $5.00 to $6.57. From a valuation perspective, the stock is trading at a premium (Forward PE: 75.0) compared to its historical average (39.8). At these levels, the market is pricing in 23.5% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, EOLS is in a strong downtrend. The price is currently testing key support at $4.56. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $17.00 (+262.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EOLS is in a strong downtrend. The price is currently testing key support at $4.56. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $17.00 (+262.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$5.00 -
$6.57
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 262.5% below Wall St target ($17.00)
- BEARISH: Market expects 23.5% growth - appears too optimistic based on history
Fair Price Analysis
30-Day Fair Range
$5.00 -
$6.57
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$4.56
Resistance Level
$5.24
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
75.04
Wall Street Target
$17.00
(+262.5%)
Revenue Growth (YoY)
12.9%
Profit Margin
-20.5%
Valuation Premium vs History
+23.5% premium
PE vs Historical
75.0 vs 39.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+23.5%
(market-implied from PE analysis)
1-Year Target
$5.79
(+24%)
2-Year Target
$7.15
(+53%)
3-Year Target
$8.83
(+88%)
3-Yr Target (if PE normalizes)
(PE: 75→40)
PE COMPRESSION
$4.69
(0%)
Earnings growth offset by PE compression
Last updated: February 01, 2026 6:47 AM ET
Data refreshes hourly during market hours. Next update: 7:47 AM
Data refreshes hourly during market hours. Next update: 7:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EOLS showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
NEUTRAL
Recent Transactions
Tomoko Yamagishi-Dressler
SELL
5722 shares
2025-08-22
Brady Stewart
BUY
30000 shares
2025-08-15
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$179 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$158 | 56 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$84 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 57 HOLD |
Advanced EOLS Option Strategies
Professional options setups generated by AI based on today's EOLS price and gamma walls.
